An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 11 Sep 2019 Planned End Date changed from 27 May 2020 to 1 Oct 2021.
- 11 Sep 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Nov 2020.
- 16 Aug 2018 Status changed from not yet recruiting to recruiting.